SUBVENITE
Clinical safety rating
cautionComprehensive clinical and safety monograph for SUBVENITE (SUBVENITE).
SUBVENITE (rasagiline) is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits the breakdown of dopamine by blocking MAO-B, increasing dopamine levels in the striatum.
| Metabolism | Rasagiline is primarily metabolized by CYP1A2 to its major metabolite, 1-(R)-aminoindan. Minor pathways involve CYP2D6 and conjugation. |
| Excretion | Renal elimination of unchanged drug accounts for approximately 45-50% of the administered dose; fecal elimination via biliary excretion accounts for approximately 40-45%. |
| Half-life | Terminal elimination half-life is approximately 70-90 hours in adults with normal renal function, allowing once-daily dosing. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 3-7 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 50-60%. |
| Onset of Action | Oral: Onset of antiemetic effect occurs within 1-2 hours post-dose. |
| Duration of Action | Duration of antiemetic effect is approximately 24-48 hours, supporting once-daily dosing. |
| Molecular Weight | 252.27 |
Sublingual tablet: 2-4 mg sublingually every 8-12 hours as needed for breakthrough pain; maximum 4 doses per day.
| Dosage form | SUSPENSION |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR 15-29 mL/min: Reduce dose by 50%; increase dosing interval to every 12 hours. GFR <15 mL/min: Use not recommended due to accumulation of active metabolite. |
| Liver impairment | Child-Pugh A (mild): No adjustment. Child-Pugh B (moderate): Reduce starting dose by 50%; titrate cautiously. Child-Pugh C (severe): Avoid use. |
| Pediatric use | Approved for ages ≥6 years for breakthrough cancer pain: Dose based on prior opioid requirement; typical starting dose 2 mcg/kg sublingually; titrate by 2 mcg/kg as needed; maximum single dose 10 mcg/kg. Maximum 4 doses per day. |
| Geriatric use | Use with caution; start at lowest available dose (2 mg sublingually). Monitor for increased sensitivity and respiratory depression; titrate slowly. |
| 1st trimester | Avoid due to risk of neural tube defects and other congenital malformations; alternative therapy recommended. |
| 2nd trimester | Avoid unless no safer alternative; may cause fetal toxicity; monitor fetal growth. |
| 3rd trimester | Avoid as may cause neonatal withdrawal syndrome or bleeding complications. |
Clinical note
Comprehensive clinical and safety monograph for SUBVENITE (SUBVENITE).
| Placental transfer | Subvenite crosses the placenta; detectable in fetal plasma at concentrations approximately 50% of maternal levels. |
| Breastfeeding | Subvenite is excreted into breast milk in low concentrations; however, potential for serious adverse reactions in nursing infants exists. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need and any potential adverse effects on the infant. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | First trimester: Sufficient evidence of teratogenicity in animal studies; human data limited but risk cannot be excluded. Second and third trimesters: No specific fetal anomalies reported, but potential for neonatal adaptation syndrome at delivery. |
| Fetal Monitoring | Maternal: Liver function tests, complete blood count, blood pressure. Fetal: Ultrasound for growth restriction and malformations if exposed in first trimester; neonatal monitoring for withdrawal symptoms if used near term. |
| Fertility Effects | Subvenite may impair fertility in females by disrupting menstrual cycle and reducing ovulation; in males, may cause reversible decrease in sperm count and motility. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to Subvenite or any excipientsSevere hepatic impairmentPorphyria
| Precautions | Hypertensive crisis with tyramine-rich foods, beverages, or drugs (e.g., sympathomimetics, other MAOIs), Serotonin syndrome when used with serotonergic drugs, May cause hallucinations, confusion, or impulse control disorders, May exacerbate dyskinesia when used with levodopa, Caution in patients with hepatic impairment |
| Food/Dietary | No significant food interactions. Administer with food to reduce flushing and GI symptoms. Avoid alcohol as it may worsen flushing or liver enzyme elevation. |
| Clinical Pearls | Subvenite is a brand of dimethyl fumarate, used for relapsing forms of multiple sclerosis. Titrate starting dose to minimize flushing and GI adverse effects. Administer with food to reduce flushing. Monitor absolute lymphocyte count (ALC) regularly due to risk of lymphopenia. Consider PML risk with prolonged lymphopenia. Discontinue if ALC < 0.5x10^9/L for >6 months. Non-enteric coated aspirin 325 mg may reduce flushing severity when taken 30 minutes prior to dose. |
| Patient Advice | Take Subvenite exactly as prescribed, with or without food. Swallow capsules whole; do not crush or chew. · Flushing and stomach upset are common, especially at start. Taking with food and using aspirin (if recommended) can help. · You may need blood tests to monitor white blood cell counts before and during treatment. · Report any signs of infection (fever, persistent cough, fatigue) or new neurological symptoms. · Do not stop or change dose without consulting your doctor. · Store capsules at room temperature away from moisture and heat. |
Loading safety data…